Drug profile · INN
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)
COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL
- Patents linked
- 0
- News articles
- 0
Quick answer
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran) (COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)
Brand COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL
Frequently asked questions
What is coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)?
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran) (COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)?
COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL is a marketed brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran). Check FDA Drugs@FDA for the current US label holder and prescribing information.